Amgen (AMGN) Receivables - Net (2009 - 2026)
Amgen (AMGN) recorded quarterly Receivables - Net of $9.1 billion in Q1 2026, down 4.51% quarter-over-quarter from $9.6 billion in Q4 2025, and up 12.37% on a YoY basis from $8.1 billion in Q1 2025.
Amgen (AMGN) Receivables - Net (2009 - 2026) Analysis & Trends
Amgen's Receivables - Net history runs 18 years deep, the most recent figure standing at $9.1 billion for Q1 2026.
- In Q1 2026, Receivables - Net rose 12.37% year-over-year to $9.1 billion; the TTM figure through Mar 2026 stood at $9.1 billion (up 12.37% YoY), while the FY2025 annual figure was $9.6 billion, up 41.11% from the prior year.
- Receivables - Net was $9.1 billion for Q1 2026 at Amgen, down from $9.6 billion in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $9.6 billion in Q4 2025 to a low of $5.1 billion in Q1 2022.
- Historically, Receivables - Net has averaged $6.9 billion across 5 years, with a median of $6.8 billion in 2024.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net dropped 6.69% in 2024, then jumped 41.11% in 2025.
- A 5-year view of Receivables - Net shows it stood at $5.6 billion in 2022, then soared by 30.65% to $7.3 billion in 2023, then retreated by 6.69% to $6.8 billion in 2024, then surged by 41.11% to $9.6 billion in 2025, then declined by 4.51% to $9.1 billion in 2026.
- The last three Receivables - Net figures came in at $9.1 billion (Q1 2026), $9.6 billion (Q4 2025), and $8.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.14 Bn |
| Mar 31, 2026 | 9.14 Bn |
| Dec 31, 2025 | 9.57 Bn |
| Dec 31, 2025 | 9.57 Bn |
| Sep 30, 2025 | 8.49 Bn |
| Sep 30, 2025 | 8.49 Bn |
| Jun 30, 2025 | 8.70 Bn |
| Jun 30, 2025 | 8.70 Bn |
| Mar 31, 2025 | 8.13 Bn |
| Mar 31, 2025 | 8.13 Bn |
| Dec 31, 2024 | 6.78 Bn |
| Dec 31, 2024 | 6.78 Bn |
| Sep 30, 2024 | 7.32 Bn |
| Sep 30, 2024 | 7.32 Bn |
| Jun 30, 2024 | 6.93 Bn |
| Jun 30, 2024 | 6.93 Bn |
| Mar 31, 2024 | 6.78 Bn |
| Mar 31, 2024 | 6.78 Bn |
| Dec 31, 2023 | 7.27 Bn |
| Dec 31, 2023 | 7.27 Bn |